Isomorphic Labs Advances AI-Designed Cancer Drug Toward Human Trials
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
Isomorphic Labs
CompanyAlso known as: Isomorphic Labs
Company Profile
Isomorphic Labs is an AI-first drug discovery company that applies advanced AI models to accelerate and improve medicine design. Founded in 2021 and headquartered in London, it combines Google DeepMind AI capabilities with pharmaceutical R&D expertise. The company positions itself around developing a world-class drug-design engine to help advance therapeutics.
- Website
- https://www.isomorphiclabs.com
- Headquarters
- London, United Kingdom
- Founded
- 2021
Related News
Novartis CEO Vas Narasimhan joins Anthropic board
Novartis chief executive Vas Narasimhan has joined Anthropic’s board. The appointment adds a pharma executive as Anthropic expands into drug discovery and launches Claude for Life Sciences.
Pharmaceutical Industry Shifts to Fewer, Larger AI-Driven Drug Development Partnerships
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Isomorphic Labs Unveils Proprietary AI Drug Discovery Model IsoDDE
Isomorphic Labs released a 27-page technical report on IsoDDE, its new AI drug-discovery engine that outperforms existing models in predicting drug-protein interactions and antibody structures, but the proprietary system offers limited technical details.
Google DeepMind Unveils IsoDDE Drug Discovery Engine, Updates Gemini Deep Think
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.